OncBioMune Pharmaceuticals Announces Shareholder Update

OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to provide shareholders an update today advising on current activities and refreshing its corporate strategy for Q4 2016.
“As represented in our most recent corporate press releases, the company is actively pursuing long-term growth through strategic acquisitions and the advancement of our ongoing clinical trials,” stated OncBioMune CEO, Dr. Jonathan Head, adding, “We are pleased and proud to provide shareholders a timely update highlighting our progress and expectations.”
Clinical Trials
Progress continues as (16) patients are now currently enrolled in the Phase 1a trial, (15) of whom have received at least one vaccine, (14) of whom have received all mandated vaccines. None of the patients that have received the vaccine on any level have experienced a dose limiting adverse event (DLAE).
Based on the positive preliminary data the Company has commenced with a significantly larger Phase 2/3 trial of ProscaVax through a previously reported Joint Venture with Vitel Laboratorios S.A. de C.V. in Mexico, a key acquisition target with which the company continues its discussions.
Additionally, the Company’s CRO partner Theradex Oncology is currently reviewing the protocol for its trial of ProscaVax in early-stage prostate cancer patients in the “active surveillance” stage of disease to be initiated at Harvard University early next year.
With a strong safety profile now established for ProscaVax and no serious adverse events reported, the Company believes they have further validated prior research in hundreds of patients showing minimal toxicity of the Company’s vaccine technology.
Acquisitions
As previously disclosed the Company has entered a shareholder’s agreement on August 19th, 2016 with Vitel Laboratorios S.A. de C.V. (“Vitel”) to acquire the Mexico-based pharmaceutical company which develops and commercializes high specialty drugs in Mexico and other Latin American countries.
Vitel is revenue positive with a drug portfolio consisting of (12) drug candidates licensed for the Mexican market. The purpose of the potential acquisition would be to develop and commercialize the ProscaVax vaccine technology and cancer technologies in Mexico, Central and Latin America (“MALA”).
Additional strategic acquisitions are currently being reviewed by the Company as it continues its focus on expanding its drug portfolio and building long-term shareholder value.
Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.